Novo Nordisk's (NVO) U.S.-listed shares fell Monday morning following the release of data for a new 澳洲幸运5官方开奖结果体彩网:phase 3 clinical trial of its in-development weight loss drug CagriSema.

In the second phase 3 study for the combination dru🐻g, the average weight loss among the roughly 1,200 patients in the study who took CagriSema was 15.7% of their body weight af🉐ter 68 weeks, compared to 3.1% for those taking a placebo.

The study from the maker of Ozempic and Wegovy follows the first Phase 3 trial 澳洲幸运5官方开奖结果体彩网:results for CagriSema in December that saw patients lose 22.7% of their body weight. Shares sank 17% following that study, as Bloomberg had reported ahead of the results that Novo Nordisk was aiming for a 25% weight loss with the new drug.

Novo Nordisk still has two more Phase 3 trials scheduled for CagriSema, and said Monday it still expects to submit the drug for regulatory approval ๊in the first quarter ♉of 2026.

Shares of the Danish drugmaker fell more than 7% Monday morning. They have risen recently following other 澳洲幸运5官方开奖结果体彩网:trial results and 澳洲幸运5官方开奖结果体彩网:solid sales of its current weight loss drugs, and ar🥃e down 3🥀9% over the last year.